Amyloid polyneuropathy caused by wild-type transthyretin

Repurposing Diflunisal for Familial Amyloid Polyneuropathy

(2015) John L. Berk et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recent progress in the understanding and treatment of transthyretin amyloidosis

(2014) Y. Sekijima   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

(2012) Teresa Coelho et al.   CURRENT MEDICAL RESEARCH AND OPINION

Amyloid Neuropathies

(2012) Susan C. Shin et al.   MOUNT SINAI JOURNAL OF MEDICINE

Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial

(2012) T. Coelho et al.   NEUROLOGY

Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients

(2011) D. Adams et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Spinal multifocal amyloidosis derived from wild-type transthyretin

(2011) Takanao Sueyoshi et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Wild-type transthyretin-derived amyloidosis in various ligaments and tendons

(2011) Takanao Sueyoshi et al.   HUMAN PATHOLOGY

High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly

(2011) Yoshiki Sekijima et al.   HUMAN PATHOLOGY

Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met

(2010) Ayako Tsuchiya-Suzuki et al.   HUMAN PATHOLOGY